Compare ACADIA Pharmaceuticals Inc. (ACAD) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs TKO Group Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while TKO Group Holdings Inc trades at $193.26 (market cap $14.51B). The key difference: TKO Group Holdings Inc is far larger — about 3.2× ACADIA Pharmaceuticals Inc.'s market cap, and TKO Group Holdings Inc pays a 1.61% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | TKO | |
|---|---|---|
Market Cap | $4.49B | $14.51B |
Sector | Health | Technology |
52-Week High | $28.06 | $224.96 |
52-Week Low | $20.06 | $155.61 |
Enterprise Value | $3.69B | $18.69B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
TKO trades at $192.30, down 1.09% today, with a bearish technical signal. The stock shows mixed earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026. Revenue grew to $4.74B in 2025, with net income of $195.40M, though high P/E of 71.49 suggests premium valuation. Recent news includes a successful WWE-UFC doubleheader and an $800M share repurchase, indicating strong operational momentum.
Outlook remains positive with 84% analyst buy ratings and a $234 consensus target, but risks include earnings volatility and competitive pressures. The stock offers growth potential through live event demand and media deals, yet investors should monitor margin sustainability amid high valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
